Nancy U. Lin, MD | Authors

January 27, 2023

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

January 27, 2023

Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.

January 20, 2023

Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.

January 20, 2023

Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.

January 13, 2023

A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.

January 13, 2023

Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.

January 06, 2023

Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.

January 06, 2023

Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.

December 30, 2022

A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.

December 30, 2022

Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.